Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
Humans
Piperazines
/ administration & dosage
Female
Pyridines
/ administration & dosage
Breast Neoplasms
/ drug therapy
Aminopyridines
/ administration & dosage
Purines
/ administration & dosage
Middle Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Retrospective Studies
Thailand
/ epidemiology
Aged
Receptor, ErbB-2
/ metabolism
Adult
Receptors, Estrogen
/ metabolism
Aromatase Inhibitors
/ administration & dosage
Receptors, Progesterone
/ metabolism
Progression-Free Survival
Breast cancer
Palbociclib
Propensity score matching
Ribociclib
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
21
06
2024
accepted:
05
08
2024
medline:
17
8
2024
pubmed:
17
8
2024
entrez:
16
8
2024
Statut:
epublish
Résumé
The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 -) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i). Direct comparison trials of different CDK4/6i are scarce. This real-world study compared the effectiveness of first-line AI plus ribociclib versus palbociclib. This multicenter retrospective cohort study, conducted in six cancer centers in Thailand, enrolled patients with HR + /HER2 - ABC treated with first-line AI, and either ribociclib or palbociclib. Propensity score matching (PSM) was performed. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), time to chemotherapy (TTC), and adverse events. Of the 250 patients enrolled, 134 patients with ribociclib and 49 patients with palbociclib were captured after PSM. Baseline characteristics were well-balanced between groups. Median PFS in patients receiving ribociclib and palbociclib were 27.9 and 31.8 months, respectively (hazard ratio: 0.87; 0.55-1.37). The median OS in the AI + ribociclib arm was 48.7 months compared to 59.1 months in the AI + palbociclib arm (hazard ratio: 0.55; 0.29-1.05). The median TTC in the AI + palbociclib group was 56 months, but not reached in the AI + ribociclib group (p = 0.42). The ORR of AI + ribociclib and AI + palbociclib were comparable (40.5% vs. 53.6%, p = 0.29). Patients receiving palbociclib demonstrated a higher proportion of neutropenia compared to those receiving ribociclib, despite a similar dose reduction rate (p = 0.28). Hepatitis rate was similar between the ribociclib (21%) and palbociclib groups (22%). Additionally, a low incidence of QT prolongation was observed in both the ribociclib (5%) and palbociclib groups (4%). This preliminary analysis of a real-world study demonstrated the comparable effectiveness of ribociclib and palbociclib with AI as an initial therapy for HR + /HER2 - ABC. No statistically significant difference in PFS, OS, and TTC was found in patients treated with AI combined with palbociclib or ribociclib. Longer follow-up and further prospective randomized head-to-head studies are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 -) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i). Direct comparison trials of different CDK4/6i are scarce. This real-world study compared the effectiveness of first-line AI plus ribociclib versus palbociclib.
METHODS
METHODS
This multicenter retrospective cohort study, conducted in six cancer centers in Thailand, enrolled patients with HR + /HER2 - ABC treated with first-line AI, and either ribociclib or palbociclib. Propensity score matching (PSM) was performed. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), time to chemotherapy (TTC), and adverse events.
RESULTS
RESULTS
Of the 250 patients enrolled, 134 patients with ribociclib and 49 patients with palbociclib were captured after PSM. Baseline characteristics were well-balanced between groups. Median PFS in patients receiving ribociclib and palbociclib were 27.9 and 31.8 months, respectively (hazard ratio: 0.87; 0.55-1.37). The median OS in the AI + ribociclib arm was 48.7 months compared to 59.1 months in the AI + palbociclib arm (hazard ratio: 0.55; 0.29-1.05). The median TTC in the AI + palbociclib group was 56 months, but not reached in the AI + ribociclib group (p = 0.42). The ORR of AI + ribociclib and AI + palbociclib were comparable (40.5% vs. 53.6%, p = 0.29). Patients receiving palbociclib demonstrated a higher proportion of neutropenia compared to those receiving ribociclib, despite a similar dose reduction rate (p = 0.28). Hepatitis rate was similar between the ribociclib (21%) and palbociclib groups (22%). Additionally, a low incidence of QT prolongation was observed in both the ribociclib (5%) and palbociclib groups (4%).
CONCLUSION
CONCLUSIONS
This preliminary analysis of a real-world study demonstrated the comparable effectiveness of ribociclib and palbociclib with AI as an initial therapy for HR + /HER2 - ABC. No statistically significant difference in PFS, OS, and TTC was found in patients treated with AI combined with palbociclib or ribociclib. Longer follow-up and further prospective randomized head-to-head studies are warranted.
Identifiants
pubmed: 39152401
doi: 10.1186/s12885-024-12765-x
pii: 10.1186/s12885-024-12765-x
doi:
Substances chimiques
Piperazines
0
ribociclib
TK8ERE8P56
palbociclib
G9ZF61LE7G
Pyridines
0
Aminopyridines
0
Purines
0
Receptor, ErbB-2
EC 2.7.10.1
Receptors, Estrogen
0
Aromatase Inhibitors
0
ERBB2 protein, human
EC 2.7.10.1
Receptors, Progesterone
0
Types de publication
Journal Article
Multicenter Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1018Informations de copyright
© 2024. The Author(s).
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: DeVita VT, Jr., Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology 9th ed. Philadelphia: Wolters Kluwer Health | Lippincott Williams & Wilkins; 2011. p. 1401–46.
NCCN. Clinical practice guidelines in oncology: breast cancer. 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast_block.pdf .
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol. 2000;18(22):3758–67.
doi: 10.1200/JCO.2000.18.22.3758
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–9.
doi: 10.1200/JCO.2003.04.194
pubmed: 12775735
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46.
doi: 10.1038/nrd4504
pubmed: 25633797
pmcid: 4480421
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.
doi: 10.1056/NEJMoa1607303
pubmed: 27959613
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50.
doi: 10.1056/NEJMoa2114663
pubmed: 35263519
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.
doi: 10.1038/s41523-018-0097-z
pubmed: 30675515
pmcid: 6336880
Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–9.
doi: 10.1158/1078-0432.CCR-21-3032
pubmed: 34965945
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994–1000.
doi: 10.1200/JCO.23.00137
pubmed: 38252901
pmcid: 10950136
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.
doi: 10.1056/NEJMoa1609709
pubmed: 27717303
Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35:718–27.
doi: 10.1016/j.annonc.2024.04.013
pubmed: 38729566
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.
doi: 10.1200/JCO.2017.73.7585
pubmed: 28580882
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–24.
doi: 10.1056/NEJMoa1911149
pubmed: 31826360
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.
doi: 10.1056/NEJMoa1810527
pubmed: 30345905
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15.
doi: 10.1016/S1470-2045(18)30292-4
pubmed: 29804902
Cejuela M, Gil-Torralvo A, Castilla M, Domínguez-Cejudo M, Falcón A, Benavent M, et al. Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int J Mol Sci. 2023;24(10):8488.
doi: 10.3390/ijms24108488
pubmed: 37239834
pmcid: 10217927
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, et al. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncol. 2023;19(10):727–36.
doi: 10.2217/fon-2022-1287
pubmed: 37133230
Lu YS, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im SA, et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. J Clin Oncol. 2024;42(23):2812–21.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–29.
doi: 10.1093/annonc/mdp322
pubmed: 19535820
pmcid: 2720818
Dieci MV, Piacentini F, Dominici M, Omarini C, Goubar A, Ficarra G, et al. Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. Anticancer Res. 2014;34(7):3657–62.
pubmed: 24982383
Makhlouf S, Quinn C, Toss M, Alsaleem M, Atallah NM, Ibrahim A, et al. Quantitative expression of oestrogen receptor in breast cancer: clinical and molecular significance. Eur J Cancer. 2024;197: 113473.
doi: 10.1016/j.ejca.2023.113473
pubmed: 38103327
Abbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, et al. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023;13(1):16719.
doi: 10.1038/s41598-023-43186-8
pubmed: 37794050
pmcid: 10550984
Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, et al. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: a Japanese phase II study. Cancer Sci. 2018;109(3):803–13.
doi: 10.1111/cas.13507
pubmed: 29345736
pmcid: 5834809
Harbeck N, Bartlett M, Spurden D, Hooper B, Zhan L, Rosta E, et al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol. 2021;17(16):2107–22.
doi: 10.2217/fon-2020-1264
pubmed: 33663223
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022;8(1):114.
doi: 10.1038/s41523-022-00479-x
pubmed: 36220852
pmcid: 9553912
Fernández-Cuerva C, Chinchilla-Alarcón T, Alcaraz-Sánchez JJ. Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival? J Oncol Pharm Pract. 2023;29(7):1619–27.
doi: 10.1177/10781552221144280
pubmed: 36476018
Jhaveri K, O’Shaughnessy J, Fasching PA, Tolaney SM, Yardley DA, Sharma VK, et al. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2023;15:17588359231216096.
doi: 10.1177/17588359231216095
pubmed: 38107828
pmcid: 10722948
Staropoli N, Geuna E, Rinaldi G, Bisagni G, Scotti V, Faggioni G, et al. Real-world clinical outcomes of ribociclib in combination with a non-steroidal aromatase inhibitor and a luteinizing hormone-releasing hormone agonist in premenopausal HR+/HER2- advanced breast cancer patients: an Italian managed access program. Curr Oncol. 2022;29(9):6635–41.
doi: 10.3390/curroncol29090521
pubmed: 36135090
pmcid: 9498176
Petrelli F, Ghidini A, Pedersini R, Cabiddu M, Borgonovo K, Parati MC, et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174(3):597–604.
doi: 10.1007/s10549-019-05133-y
pubmed: 30659432
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, et al. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR(+)/HER2(-) advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019;19(5):317-25.e4.
doi: 10.1016/j.clbc.2019.04.005
pubmed: 31104984
Seki H, Sakurai T, Maeda Y, Oki N, Aoyama M, Yamaguchi R, et al. Efficacy and safety of palbociclib and fulvestrant in Japanese patients with ER+/HER2- advanced/metastatic breast cancer. In Vivo. 2019;33(6):2037–44.
doi: 10.21873/invivo.11701
pubmed: 31662535
pmcid: 6899113
Taylor-Stokes G, Mitra D, Waller J, Gibson K, Milligan G, Iyer S. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Breast. 2019;43:22–7.
doi: 10.1016/j.breast.2018.10.009
pubmed: 30391832
Groenland SL, Martínez-Chávez A, van Dongen MGJ, Beijnen JH, Schinkel AH, Huitema ADR, et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib. Clin Pharmacokinet. 2020;59(12):1501–20.
doi: 10.1007/s40262-020-00930-x
pubmed: 33029704
Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in Breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317–31.
doi: 10.1007/s40265-020-01461-2
pubmed: 33369721
Low JL, Lim E, Bharwani L, Wong A, Wong K, Ow S, et al. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia. Ther Adv Med Oncol. 2022;14:17588359221139678.
doi: 10.1177/17588359221139678
pubmed: 36570409
pmcid: 9772978
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, et al. Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer. Clin Breast Cancer. 2022;22(8):792–800
doi: 10.1016/j.clbc.2022.08.011
pubmed: 36151018